---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000034"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:33:44.850593+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Q1 net loss $62M; cash $376.8M; reni-cel adult cohort enrollment complete

## Summary
- Q1 2024 net loss $62.0M ($0.76/share) vs $49.0M ($0.71) in Q1 2023; collaboration revenue fell to $1.1M from $9.9M.
- Cash, equivalents, and marketable securities $376.8M at March 31, 2024; runway into 2026.
- R&D expenses rose to $48.8M from $37.8M driven by reni-cel clinical and manufacturing costs.
- Completed adult cohort enrollment in RUBY trial for sickle cell disease; enrolled multiple adolescent patients.
- Extended Bristol Myers Squibb collaboration by two years; CAFC oral arguments held for CRISPR patent interference.

## SEC filing metadata
- accession: 0001650664-24-000034
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/0001650664-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/edit-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000034
- JSON: https://secwatch.observer/filing/0001650664-24-000034.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000034.txt

## Key facts
- Earnings Releases
  Editas Medicine, Inc. reported first quarter 2024 results: net income net loss of $62.0 million, EPS -$0.76.
  - Period: first quarter 2024
  - Net income: net loss of $62.0 million
  - EPS: -$0.76
  - Result: reported results
  source text: For the three months ended March 31, 2024, net loss attributable to common stockholders was $62.0 million, or $0.76 per share, compared to net loss of $49.0 million, or $0.71 per share, for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/0001650664-24-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.